Welcome to our dedicated page for Baxter Intl SEC filings (Ticker: BAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Baxter International Inc. (NYSE: BAX) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered summaries to help interpret complex documents. Baxter is a global medtech company with common stock and certain global notes registered under Section 12(b) of the Exchange Act, and its filings offer insight into capital structure, financing activities, governance and key business developments.
Investors reviewing Baxter’s filings will find Form 8-K reports covering topics such as new senior note offerings due 2029, 2030 and 2035, amendments to credit agreements, tender offers for existing senior unsecured notes due 2026 and 2027, and repayment of a term loan facility. Other 8-Ks detail changes in executive leadership, earnings press releases furnished under Item 2.02, and updates to leverage covenants. These documents outline how Baxter manages its debt profile, liquidity and capital allocation, including refinancing transactions and tender offer results.
Baxter’s filings also confirm its status as a Delaware corporation and list its securities registered on the New York Stock Exchange, including common stock under the symbol BAX and 1.3% global notes due 2029. Disclosures about note terms, ranking, optional redemption provisions, change-of-control repurchase rights and covenants are contained in indentures and supplemental indentures referenced in the exhibits to Form 8-K.
On Stock Titan, AI-generated highlights help users quickly identify key points in Baxter’s 10-K and 10-Q reports (when available), such as segment information, risk factors and liquidity discussions, while Form 4 insider transaction filings can be used to monitor trading by directors and officers. Real-time updates from EDGAR ensure that new Baxter filings appear promptly, and AI summaries provide plain-language explanations of technical sections, helping users understand what each filing may mean for Baxter’s financial obligations, governance and strategic actions.
FMR LLC filed a Schedule 13G reporting beneficial ownership of 34,811,770.04 shares of Baxter International Inc. common stock, representing 6.8% of the class as of the event dated 12/31/2025.
FMR LLC has sole voting power over 23,858,435.30 shares and sole dispositive power over 34,811,770.04 shares. Abigail P. Johnson is also reported as a beneficial owner with sole dispositive power over the same 34,811,770.04 shares. The securities are stated to be held in the ordinary course of business and not for the purpose of changing or influencing control of Baxter.
BlackRock Portfolio Management LLC, a Delaware entity, reports beneficial ownership of 44,925,341 shares of Baxter International Inc. common stock, representing 8.7% of the class as of 12/31/2025.
The firm has sole power to vote 44,289,706 shares and sole power to dispose of 44,925,341 shares, with no shared voting or dispositive power. The holding is reported as being acquired and held in the ordinary course of business, not for the purpose of changing or influencing control of Baxter.
Various underlying clients have rights to dividends or sale proceeds from these shares, but no single client is stated to have more than five percent of Baxter’s outstanding common stock.
Pzena Investment Management, LLC reports beneficial ownership of 70,866,049 shares of Baxter International Inc. common stock, representing 13.8% of the class as of December 31, 2025. Pzena has sole voting power over 58,815,905 shares and sole dispositive power over the full 70,866,049 shares, with no shared voting or dispositive power.
The filing states that the securities were acquired and are held in the ordinary course of business, and not for the purpose of changing or influencing control of Baxter. Pzena’s clients have the right to receive dividends and sale proceeds from these securities, but no single client has an interest in more than five percent of Baxter’s outstanding common stock.
Baxter International Inc. completed the final settlement of its previously announced cash tender offers for certain senior notes. On December 22, 2025, the company purchased an additional $2,610,000 aggregate principal amount of its 2.600% senior unsecured notes due 2026 at a price of $960.50 per $1,000 of principal, plus accrued interest. Earlier, on December 8, 2025, Baxter had already bought $420,589,000 of the 2026 notes and $614,370,000 of its 1.915% senior unsecured notes due 2027. The company has now satisfied and discharged all outstanding 2026 notes, and the 2027 tender offer was fully subscribed as of the early tender date, with no additional 2027 notes accepted after that.
Baxter International executive Jeanne K. Mason, EVP and Chief HR Officer, reported an insider share forfeiture. On 12/12/2025 she forfeited 650 shares of Baxter common stock at $19.15 per share to cover Federal Insurance Contributions Act (FICA) taxes on restricted stock unit awards previously granted under Baxter International Inc.'s Long-Term Incentive Plan. After this tax withholding transaction, she beneficially owns 199,853 Baxter shares, and this total includes the automatic reinvestment of dividends.
Baxter International Inc. reported the initial beneficial ownership of one of its officers, the Group President, ITT & Pharma, as of 12/01/2025. The reporting person directly owns 54,623 shares of Baxter common stock, $1 par value.
The filing also lists stock options. One option grants the right to buy 15,353 shares of common stock at an exercise price of $39.06, becoming exercisable in three equal annual installments beginning on 03/01/2024 and expiring on 03/01/2033. A second option covers 23,787 shares at an exercise price of $35.44, vesting in three equal annual installments beginning on 03/06/2026 and expiring on 03/06/2035.
Baxter International Inc. has completed a major debt refinancing, issuing $300,000,000 of 4.450% Senior Notes due 2029, $700,000,000 of 4.900% Senior Notes due 2030 and $1,000,000,000 of 5.650% Senior Notes due 2035 under an existing shelf registration. The company received approximately $1.99 billion in net proceeds from these notes.
Baxter plans to use the proceeds to fund cash tender offers for its 2.600% senior unsecured notes due 2026 and a portion of its 1.915% senior unsecured notes due 2027, to discharge any 2026 notes not purchased, and to refinance its term loan credit facility. On December 4, 2025, it fully repaid all outstanding obligations under that term loan. Any remaining proceeds are earmarked for general corporate purposes and repayment of other indebtedness, effectively extending the company’s debt maturities and reshaping its capital structure.
Baxter International Inc. reported that it entered into Amendment No. 1 to its amended and restated five-year credit agreement dated June 11, 2025. The amended agreement, with JPMorgan Chase Bank, N.A. as administrative agent and various lenders, revises the net leverage ratio covenant. Specifically, it increases the maximum net leverage ratio that applies for the four fiscal quarters ending on December 31, 2025, March 30, 2026, June 30, 2026 and September 30, 2026. This change provides Baxter with more room under its leverage test during this period while it continues to operate under the existing credit facility.
Baxter International Inc. increased the Maximum Tender Cap for its previously announced cash tender offer for its 1.915% senior unsecured notes due 2027 to $600 million, up from the prior cap of $300 million. This means Baxter is now willing to buy back a larger amount of these 2027 notes for cash than originally planned.
The change, announced on November 19, 2025, affects only the 1.915% notes due 2027 and is governed by the company’s offer to purchase dated the same day. The update is described as part of a tender offer process rather than an offer to sell or solicit new securities.
Baxter International Inc. announced that it has started cash tender offers for certain outstanding debt securities. The company is offering to purchase any and all of its 2.600% senior unsecured notes due 2026 and a portion of its 1.915% senior unsecured notes due 2027, for an aggregate purchase price of up to $300 million, an amount that may be increased, decreased or eliminated under the terms of its offer to purchase dated November 19, 2025. The tender offers are being made only under that offer to purchase and are subject to applicable securities and other laws in relevant jurisdictions.